114,600 Shares in Royalty Pharma plc (NASDAQ:RPRX) Bought by ING Groep NV

ING Groep NV purchased a new stake in Royalty Pharma plc (NASDAQ:RPRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 114,600 shares of the biopharmaceutical company’s stock, valued at approximately $2,923,000.

A number of other institutional investors also recently modified their holdings of RPRX. Brooklyn Investment Group grew its holdings in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP boosted its position in Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 877 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 943 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 997 shares during the last quarter. Finally, Spire Wealth Management lifted its position in shares of Royalty Pharma by 377.6% in the fourth quarter. Spire Wealth Management now owns 2,149 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 1,699 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Price Performance

Shares of RPRX opened at $33.42 on Friday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The company’s fifty day simple moving average is $29.18 and its 200 day simple moving average is $27.94. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $33.69. The company has a market cap of $19.26 billion, a price-to-earnings ratio of 23.05, a PEG ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s payout ratio is 57.93%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.